# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Buy rating and announce...
Leerink Partners analyst Mani Foroohar initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and an...
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Overweight rating and anno...
Revenue $0 Down From
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $...
- SEC Filing
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...